Charge variants of an avastin biosimilar isolation, characterization, in vitro properties and pharmacokinetics in rat

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Zhao, Yan Yan ^a,b   Wang, Ning ^a   Liu, Wan Hui ^a,b   Tao, Wen Jie ^b   Liu, Li Li ^b   Shen, Zhen Duo ^b  

^a YANTAI UNIVERSITY   (China)

^b Shandong Luye Pharmaceutical Company Limited   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT;

ANIMAL; CAPILLARY ELECTROPHORESIS; CELL PROLIFERATION; DRUG EFFECT; ION EXCHANGE CHROMATOGRAPHY; ISOELECTRIC FOCUSING; MALE; RAT; SPRAGUE DAWLEY RAT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BEVACIZUMAB; BIOSIMILAR PHARMACEUTICALS; CELL PROLIFERATION; CHROMATOGRAPHY, ION EXCHANGE; ELECTROPHORESIS, CAPILLARY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; ISOELECTRIC FOCUSING; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84991569402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151874     Document Type: Article

References (45)

1. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody–based cancer immunotherapy J]. Molecular cancer therapeutics, 2004, 3(11): 1493–1501. PMID: 15542788
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity[J]. nature, 1975, 256(5517): 495–497. PMID: 1172191
3. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation [J]. Pharmaceutical research, 2001, 18(9): 1345–1353. PMID: 11683251
4. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody[J]. Journal of Chromatography B: Biomedical Sciences and Applications, 2001, 752(2): 233–245. PMID: 11270864
5. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies [J]. Journal of pharmaceutical sciences, 2008, 97(7): 2426–2447. PMID: 17828757
6. Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods [J]. Current pharmaceutical biotechnology, 2008, 9(6): 468–481. PMID: 19075686
7. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats[C]//MAbs. Taylor & Francis, 2010, 2(6): 613–624.
8. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA, et al. Effects of charge on antibody tissue distribution and pharmacokinetics [J]. Bioconjugate chemistry, 2010, 21(12): 2153–2163. doi: 10.1021/bc100261d PMID: 21053952
9. Hong G, Bazin-Redureau MI, Scherrmann JMG. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and fab fragments in rat [J]. Journal of pharmaceutical sciences, 1999, 88(1): 147–153. PMID: 9874717
10. Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JW, King HD, et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations[J]. Proceedings of the National Academy of Sciences, 1986, 83(8): 2632–2636.
11. Gangopadhyay A, Petrick AT, Thomas P. Modification of antibody isoelectric point affects biodistribution of 111-indium-labeled antibody [J]. Nuclear medicine and biology, 1996, 23(3): 257–261. PMID: 8782234
12. Presta LG, Chen H, O'connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer research, 1997, 57(20): 4593–4599. PMID: 9377574
13. Suzuki H, Hirashima T, Kobayashi M, Okamoto N, Matsuura Y, Tamiya M, et al. Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases[J]. Molecular and clinical oncology, 2013, 1(3): 480–482. PMID: 24649195
14. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, et al. PhaseI clinical trial of bendamustine and bevacizumab for patients with advanced cancer [J]. Journal of the National Comprehensive Cancer Network, 2014, 12(2): 194–203. PMID: 24586081
15. Dhillon S. Bevacizumab combination therapy: A review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer [J]. BioDrugs, 2013, 27(4): 375–392. doi: 10.1007/s40259-013-0043-4 PMID: 23728884
16. Guélat B, Ströhlein G, Lattuada M, Delegrange L, Valax P, Morbidelli M. Simulation model for overloaded monoclonal antibody variants separations in ion-exchange chromatography [J]. Journal of Chromatography A, 2012, 1253: 32–43. doi: 10.1016/j.chroma.2012.06.081 PMID: 22795935
17. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R, Brasky K, et al. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region, Infect. Immun. 73 (2005) 8362–8368. PMID: 16299334
18. Karlsson R., Fält A., Experimental design for kinetic analysis of protein–protein interactions with surface plasmon resonance biosensors, J. Immunol. Methods 200 (1997) 121–133 PMID: 9005951
19. Kiyoshi M, Caaveiro JM, Miura E, Nagatoishi S, Nakakido M, Soga S, et al. Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex [J]. PloS one, 2014, 9(1)
20. Fekete S, Gassner AL, Rudaz S, Schappler J, Guillarme D. Analytical strategies for the characterization of therapeutic monoclonal antibodies[J]. TrAC Trends in Analytical Chemistry, 2013, 42: 74–83.
21. Moorhouse KG, Nashabeh W, Deveney J, Bjork NS, Mulkerrin MG, Ryskamp T. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDECC2B8 after papain digestion[J]. Journal of pharmaceutical and biomedical analysis, 1997, 16(4): 593–603. PMID: 9502155
22. Lau H, Pace D, Yan B, McGrath T, Smallwood S, Patel K, et al. Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC [J]. Journal of Chromatography B, 2010, 878(11): 868–876.
23. Teshima G, Li M X, Danishmand R, Obi C, To R, Huang C, et al. Separation of oxidized variants of a monoclonal antibody by anion-exchange [J]. Journal of Chromatography A, 2011, 1218(15): 2091–2097. doi: 10.1016/j.chroma.2010.10.107 PMID: 21145555
24. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles [J]. Analytical biochemistry, 1996, 240(2): 210–226. PMID: 8811911
25. 1 [J]. Electrophoresis, 2014, 35(7): 1072–1078. PMID: 24812686
26. Michels DA, Salas-Solano O, Felten C. Imaged capillary isoelectric focusing for charge-variant analysis of biopharmaceuticals [J]. BioProcess Int, 2011, 9(10): 48–54.
27. Falcao M, Soares R, Azevedo I, FALCAO-REIS F, Carneiro A. Effects of bevacizumab on HUVEC migration and capillary formation [J]. Acta Ophthalmologica Scandinavica, 2007, 85(s240): 0–0.
28. Inoue S, Hartman A, Branch CD, Bucana CD, Bekele BN, Stephens LC, et al. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft[J]. Molecular Therapy, 2007, 15(2): 287–294. PMID: 17235306
29. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro[J]. Angiogenesis, 2004, 7(4): 335–345. PMID: 15886877
30. Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology [J]. Investigational new drugs, 2014, 32(5): 851–859. doi: 10. 1007/s10637-014-0129-y PMID: 24994097
31. Linke T, Feng J, Yu K, Kim H J, Wei Z, Wang Y, et al. Process scale separation of an anti-CD22 immunotoxin charge variant[J]. Journal of Chromatography A, 2012, 1260: 120–125. doi: 10.1016/j.chroma. 2012.08.061 PMID: 22980642
32. Zhang T, Bourret J, Cano T. Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography [J]. Journal of Chromatography A, 2011, 1218(31): 5079–5086. doi: 10.1016/j.chroma.2011.05.061 PMID: 21700290
33. Wacker C, Berger CN, Girard P, Meier R. Glycosylation profiles of therapeutic antibody pharmaceuticals [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79(3): 503–507. doi: 10. 1016/j.ejpb.2011.06.010 PMID: 21745568
34. Sosic Z, Houde D, Blum A, Carlage T, Lyubarskaya Y. Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity[J]. Electrophoresis, 2008, 29(21): 4368–4376. doi: 10.1002/elps.200800157 PMID: 19016565
35. Kaschak T, Boyd D, Lu F, Derfus G, Kluck B, Nogal B, et al. Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media[C]//MAbs. Taylor & Francis, 2011, 3(6): 577–583.
36. Tinsley J, Robinson N, Davies K E. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-aryl-benzoxazole utrophin modulator, following single-and multiple-dose administration to healthy male adult volunteers [J]. The Journal of Clinical Pharmacology, 2015, 55(6): 698–707. doi: 10.1002/jcph. 468 PMID: 25651188
37. Espinosa-de la Garza CE, Perdomo-Abúndez FC, Padilla-Calderón J, Uribe-Wiechers JM, Pérez NO, Flores-Ortiz LF, et al. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis [J]. Electrophoresis, 2013, 34(8): 1133–1140. doi: 10.1002/elps.201200575 PMID: 23417502
38. Zhao SS, Chen DDY. Applications of capillary electrophoresis in characterizing recombinant protein therapeutics [J]. Electrophoresis, 2014, 35(1): 96–108. doi: 10.1002/elps.201300372 PMID: 24123141
39. Tangarone B. Development of a CE charge heterogeneity method for a challenging protein. Paper presented at IBC 12th Well Characterized Biologicals 2008; Reston, VA.
40. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification [J]. Annals of neurology, 2010, 68(3): 295–303. doi: 10.1002/ana.22128 PMID: 20737510
41. Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung H P, Wiendl H, et al. An assay to quantify species-specific anti-JC virus antibody levels in MS patients [J]. Multiple Sclerosis Journal, 2013, 19(9): 1137–1144. doi: 10.1177/1352458513475489 PMID: 23388163
42. Heng S, Dynon K, Li Y, Edgell T, Walton K, Rombauts LJ, et al. Development of a high-throughput assay for human proprotein convertase 5/6 for detecting uterine receptivity[J]. Analytical biochemistry, 2015, 475: 14–21. doi: 10.1016/j.ab.2014.12.012 PMID: 25554488
43. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YMC. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010; 28:509–16. doi: 10.1016/j.tibtech.2010.07.001 PMID: 20691488
44. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2 and -3 antibodies modified with biotin. Cancer Biother Radiopharm 2002; 17:359–70. PMID: 12396700
45. Dou P, Liu Z, He J, Xu JJ, Chen HY. Rapid and high-resolution glycoform profiling of recombinant human erythropoietin by capillary isoelectric focusing with whole column imaging detection [J]. Journal of Chromatography A, 2008, 1190(1): 372–376.